Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: The effect of PEG-400 on carbamazepine absorption

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 2, 2012, Pages 386-391

  Beig, Avital ^a   Miller, Jonathan M ^b   Dahan, Arik ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Drug solubility; Intestinal permeability; Oral absorption; Solubility enabling formulations; Solubility permeability tradeoff

Indexed keywords

CARBAMAZEPINE; MACROGOL 400;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABSORPTION; DRUG DIFFUSION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; MALE; MEMBRANE PERMEABILITY; NONHUMAN; RAT; VISCOSITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; CARBAMAZEPINE; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; DIFFUSION; INTESTINAL ABSORPTION; JEJUNUM; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SOLUBILITY; SOLVENTS; THERMODYNAMICS; WATER;

EID: 84861593280     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.02.012     Document Type: Article

References (32)

1. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharmaceutical Research 12 1995 413
2. A. Dahan, J.M. Miller, and G.L. Amidon Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs AAPS Journal 11 2009 740 746
3. R. Lobenberg, and G.L. Amidon Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards European Journal of Pharmaceutics and Biopharmaceutics 50 2000 3 12
4. M.N. Martinez, and G.L. Amidon A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals Journal of Clinical Pharmacology 42 2002 620 643
5. A. Dahan, and A. Hoffman Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs Journal of Controlled Release 129 2008 1 10
6. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Advanced Drug Delivery Reviews 46 2001 3 26
7. A. Dahan, J.M. Miller, A. Hoffman, G.E. Amidon, and G.L. Amidon The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone Journal of Pharmaceutical Sciences 99 2010 2739 2749
8. J.M. Miller, A. Beig, B.J. Krieg, R.A. Carr, T. Borchardt, G.E. Amidon, G.L. Amidon, and A. Dahan The solubility-permeability interplay: Mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation Molecular Pharmaceutics 8 2011 1848 1856
9. A. Dahan, and A. Hoffman The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats European Journal of Pharmaceutics and Biopharmaceutics 67 2007 96 105
10. G.E. Amidon, W.I. Higuchi, and N.F.H. Ho Theoretical and experimental studies of transport of micelle-solubilized solutes Journal of Pharmaceutical Sciences 71 1982 77 84
11. D.R. Mudra, and R.T. Borchardt Absorption barriers in the rat intestinal mucosa. 3: Effects of polyethoxylated solubilizing agents on drug permeation and metabolism Journal of Pharmaceutical Sciences 99 2010 1016 1027
12. B.D. Rege, J.P.Y. Kao, and J.E. Polli Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers European Journal of Pharmaceutical Sciences 16 2002 237 246
13. K. Yano, Y. Masaoka, M. Kataoka, S. Sakuma, and S. Yamashita Mechanisms of membrane transport of poorly soluble drugs: role of micelles in oral absorption processes Journal of Pharmaceutical Sciences 99 2010 1336 1345
14. Y. Gao, R.A. Carr, J.K. Spence, W.W. Wang, T.M. Turner, J.M. Lipari, and J.M. Miller A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling Molecular Pharmaceutics 7 2010 1516 1526
15. J.R. Crison, V.P. Shah, J.P. Skelly, and G.L. Amidon Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine Journal of Pharmaceutical Sciences 85 1996 1005 1011
16. V.G. Levich Physico-Chemical Hydrodynamics 1962 Prentice-Hall Englewood Cliffs, NJ pp. 39-72
17. J.M. Miller, A. Dahan, D. Gupta, S. Varghese, and G.L. Amidon Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs Journal of Controlled Release 137 2009 31 37
18. F. Wohnsland, and B. Faller High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes Journal of Medicinal Chemistry 44 2001 923 930
19. A. Dahan, and G.L. Amidon Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting American Journal of Physiology - Gastrointestinal and Liver Physiology 297 2009 G371 G377
20. A. Dahan, and G.L. Amidon Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs Molecular Pharmaceutics 6 2009 19 28
21. A. Dahan, J.M. Miller, J.M. Hilfinger, S. Yamashita, L.X. Yu, H. Lennernäs, and G.L. Amidon High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations Molecular Pharmaceutics 7 2010 1827 1834
22. A. Dahan, and G.L. Amidon Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of P-glycoprotein Pharmaceutical Research 26 2009 883 892
23. H. Lennernas Human intestinal permeability Journal of Pharmaceutical Sciences 87 1998 403 410
24. I. Komiya, J. Park, A. Kamani, N. Ho, and W. Higuchi Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes International Journal of Pharmaceutics 4 1980 249 262
25. J.M. Miller, A. Beig, R.A. Carr, G.K. Webster, and A. Dahan The solubility-permeability interplay when using cosolvents for solubilization: Revising the way we use solubility-enabling formulations Molecular Pharmaceutics 2012 10.1021/mp200460u
26. U. Fagerholm, and H. Lennernäs Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption European Journal of Pharmaceutical Sciences 3 1995 247 253
27. H. Lennernas Human jejunal effective permeability and its correlation with preclinical drug absorption models Journal of Pharmacy and Pharmacology 49 1997 627 638
28. H. Lennernäs, Ö. Ahrenstedt, R. Hällgren, L. Knutson, M. Ryde, and L.K. Paalzow Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man Pharmaceutical Research 9 1992 1243 1251
29. W. Elmquist, L. Riad, I. Leppik, and R. Sawchuk Physiological modelling of the dependence of renal clearance on urine flow: carbamazepine and two metabolites in man Pharmaceutical Research 5 Suppl. 1988 S217
30. L.E. Riad, and R.J. Sawchuk Effect of polyethylene glycol 400 on the intestinal permeability of carbamazepine in the rabbit Pharmaceutical Research 8 1991 491 497
31. A. Dahan, and J.M. Miller The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs AAPS Journal 2012 10.1208/s12248-012-9337-6
32. J.M. Miller, and A. Dahan Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: Model validation International Journal of Pharmaceutics 2012 10.1016/j.ijpharm.2012. 03.017